Medicare won't change coverage policy for pricey Alzheimer's drugs

Medicare will continue to restrict coverage of a new class of Alzheimer’s drugs, even when they have been fully approved by the Food and Drug Administration (FDA). The Centers for Medicare and Medicaid Services (CMS) said in a statement Thursday that it will cover the drugs once they are fully approved, but it will also […]

Veterans Affairs will cover pricey experimental Alzheimer's drug

The Veterans Health Administration (VHA) said it will widely cover an experimental $26,500-per-year Alzheimer’s drug, even though Medicare will not. Leqembi will be made available to veterans living with early stages of Alzheimer’s disease who meet agency criteria as well as conditions on Leqembi’s label, according to an announcement Monday by the drug’s manufacturers Eisai […]